These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Re-emergence of visceral leishmaniasis in Gujarat, India. Sharma U; Redhu NS; Mathur P; Singh S J Vector Borne Dis; 2007 Sep; 44(3):230-2. PubMed ID: 17896628 [No Abstract] [Full Text] [Related]
44. Current clinical, laboratory, and treatment outcome characteristics of visceral leishmaniasis: results from a seven-year retrospective study in Greece. Georgiadou SP; Stefos A; Spanakos G; Skrimpas S; Makaritsis K; Sipsas NV; Dalekos GN Int J Infect Dis; 2015 May; 34():46-50. PubMed ID: 25743761 [TBL] [Abstract][Full Text] [Related]
45. Visceral Leishmaniasis Masquerading as Drug-Induced Pancytopenia in Lung Cancer Patients. Laroumagne S; Tronchetti J; Dutau H; Astoul P Curr Oncol; 2024 Apr; 31(4):2274-2277. PubMed ID: 38668071 [TBL] [Abstract][Full Text] [Related]
46. A travel misadventure--visceral leishmaniasis in an immunocompetent patient. Delacour H; Roche C; Roche B; Morand C; Koeck JL J R Army Med Corps; 2010 Sep; 156(3):169-71. PubMed ID: 20919619 [TBL] [Abstract][Full Text] [Related]
47. Visceral leishmaniasis in immunosuppressed Caucasian patient. Toqeer M; Rahman N; Whitehead MW; Lockwood D BMJ Case Rep; 2012 May; 2012():. PubMed ID: 22605859 [TBL] [Abstract][Full Text] [Related]
48. Current approaches to visceral leishmaniasis treatment in solid organ transplant recipients. Clemente WT; Mourão PHO; Aguado JM Expert Rev Anti Infect Ther; 2018 May; 16(5):391-397. PubMed ID: 29737887 [TBL] [Abstract][Full Text] [Related]
49. Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia. Tamiru A; Tigabu B; Yifru S; Diro E; Hailu A BMC Infect Dis; 2016 Oct; 16(1):548. PubMed ID: 27724891 [TBL] [Abstract][Full Text] [Related]
50. [Treatment of visceral leishmaniasis in children]. Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279 [TBL] [Abstract][Full Text] [Related]
51. Treatment of visceral leishmaniasis: options and choice. Bhattacharya SK; Dash AP Lancet Infect Dis; 2016 Feb; 16(2):142-3. PubMed ID: 26867454 [No Abstract] [Full Text] [Related]
52. Leishmaniasis: an update of current pharmacotherapy. Sundar S; Chakravarty J Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501 [TBL] [Abstract][Full Text] [Related]
53. Visceral Leishmaniasis in A Patient Presenting with Fever of Unknown Origin: A Case Report From a Low-endemic Region of Turkey. Jaiteh MB; Çalık Başaran N; Özışık L; Akman O; Hasanlı N; Tortop S; Özmen Çapın BB; Hüseyinova S; Üner A; İnkaya AÇ Turkiye Parazitol Derg; 2019 Dec; 43(4):210-212. PubMed ID: 31865658 [TBL] [Abstract][Full Text] [Related]
54. Visceral leishmaniasis during pregnancy: A rare case report from Greece. Panagopoulos P; Mitsopoulos V; Papadopoulos A; Theodorou S; Christodoulaki C; Aloupogiannis K; Papantoniou N PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005134. PubMed ID: 28207741 [No Abstract] [Full Text] [Related]
55. You're the flight surgeon: visceral leishmaniasis. Zaleski SD Aviat Space Environ Med; 2012 Apr; 83(4):454-5. PubMed ID: 22462377 [No Abstract] [Full Text] [Related]
56. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis. Brogden RN; Goa KL; Coukell AJ Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313 [TBL] [Abstract][Full Text] [Related]